Kaplan Brett 4

4 · Prevail Therapeutics Inc. · Filed Jan 26, 2021

Form 4

Period: 2021-01-22

Chief Financial Officer

Transactions

Disposition to Issuer
Stock Option (Right to Buy)
2021-01-22−347,004→ 0 total
Exercise: $0.18→ Common Stock (347,004 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2021-01-22−64,565→ 0 total
Exercise: $10.26→ Common Stock (64,565 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2021-01-22−95,000→ 0 total
Exercise: $16.91→ Common Stock (95,000 underlying)

Footnotes (1)

[F1]Pursuant to the terms of the Merger Agreement, and as of immediately prior to the Effective Time, each of these options, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of the Reporting Person, and the Reporting Person was entitled to receive (A) an amount of cash (less applicable tax withholdings) equal to the product of (i) the excess, if any, of $22.50 per share of common stock underlying such stock option, net in cash, without interest, over the applicable exercise price per share underlying such stock option multiplied by (ii) the total number of shares subject to such stock option, and (B) one contingent value right per share for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting).

Documents

1 file